In conclusion, the DPP-4 inhibitor sitagliptin in a dose of 50 mg orally per day for 3 months was a safe add-on therapy to the AHCL system for adolescents with type 1 diabetes and diabetic nephropathy. The gene discussed is DPP4; the disease is diabetic kidney disease.